Compare CKX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | MRKR |
|---|---|---|
| Founded | 1930 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 16.6M |
| IPO Year | 1998 | N/A |
| Metric | CKX | MRKR |
|---|---|---|
| Price | $10.45 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.25 |
| AVG Volume (30 Days) | 2.8K | ★ 269.7K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.14 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | $897,333.00 | ★ $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.06 |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $0.81 |
| 52 Week High | $14.00 | $5.95 |
| Indicator | CKX | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 66.06 |
| Support Level | $8.66 | $1.15 |
| Resistance Level | $10.39 | $1.27 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 80.80 | 95.26 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. CKX has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Surface segment. Geographically, it generates all of its revenue from the United States of America.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.